New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:26 EDTIARTIntegra LifeSciences new products should boost sales, margins, says Argus
Argus believes that new products in Integra's Extremities and Spinal portfolios should boost its sales and gross margins. The firm expects the company's margin to expand in 2014, and keeps a Buy rating on the stock.
News For IART From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
06:09 EDTIARTOsiris assumed with a Hold from Buy at Brean Capital
Brean Capital analyst Jason Wittes downgraded Osiris Therapeutics (OSIR) to Hold after assuming coverage of the name. The analyst views the stock as fairly valued at current levels and sees increased competition from Integra LifeSciences' (IART) entry into the diabetic foot ulcer market.
September 30, 2015
11:48 EDTIARTFTC requires divestitures as condition of Wright Medical, Tornier merger
Wright Medical Group (WMGI) and Tornier (TRNX) have agreed to sell Tornier's U.S. rights and assets related to its total ankle replacements and total silastic toe joint replacements to resolve Federal Trade Commission charges that the proposed $3.3B merger would illegally reduce competition for these devices, the FTC announced. Under the proposed settlement, Wright and Tornier will divest the rights and assets to these devices to Integra Lifesciences (IART) and provide Integra with intellectual property, manufacturing technology, and existing inventory, as well as other assets and assistance to ensure that Integra can effectively compete in the markets. The proposed order also requires Wright and Tornier to supply Integra with total ankle replacements for up to three years and total silastic toe joint replacements for up to a year, while Integra transitions to become an independent competitor in these markets.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use